Phaseline

Companies › Ferring Pharmaceuticals

Ferring Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 3, 2 Phase 1; Oncology, Gastroenterology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nadofaragene Firadenovec
Interferon alpha-2 exogenous gene
IFNA2Phase 3Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Intermediate Risk Non-Muscle Invasive Bladder Cancer; Bladder Cancer; Low-grade Upper Tract Urothelial Carcinoma …Jun 2028
CLENPIQ
Osmotic laxative containing sodium picosulfate, magnesium oxide, and citric acid
–Phase 1Bowel PreparationDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04113382CLENPIQPhase 1Bowel PreparationGastroenterologyDec 2027
NCT06929286Nadofaragene FiradenovecPhase 3Non-Muscle Invasive Bladder CancerOncologyApr 2028
NCT06545955Nadofaragene FiradenovecPhase 3Non-muscle Invasive Bladder Cancer With Carcinoma in SituOncologyJun 2028
NCT06510374Nadofaragene FiradenovecPhase 3Intermediate Risk Non-Muscle Invasive Bladder CancerOncologySep 2028
NCT05704244Nadofaragene FiradenovecPhase 3Bladder CancerOncologyNov 2029
NCT06668493Nadofaragene FiradenovecPhase 1Low-grade Upper Tract Urothelial CarcinomaOncologyNov 2029

From the company's SEC filings

Complete response letters from FDA

Targets

IFNA2 (1)

Companies with the same targets

–

Companies built like this

Xuanzhu Biopharmaceutical Zhejiang Doer Biologics Hinova Pharmaceuticals Norroy Bioscience Onconic Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.